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Metoprolol prevents sodium retention induced by lower body
negative pressure in healthy men.
Background. Lower body negative pressure (LBNP) has
been shown to induce a progressive activation of neurohor-
monal systems, and a renal tubular and hemodynamic response
that mimics the renal adaptation observed in congestive heart
failure (CHF). As beta-blockers play an important role in the
management of CHF patients, the effects of metoprolol on the
renal response were examined in healthy subjects during sus-
tained LBNP.
Methods. Twenty healthy male subjects were randomized in
this double blind, placebo versus metoprolol 200 mg once daily,
study. After 10 days of treatment, each subject was exposed to
3 levels of LBNP (0, −10, and −20 mbar) for 1 hour, each level
of LBNP being separated by 2 days. Neurohormonal profiles,
systemic and renal hemodynamics, as well as renal sodium han-
dling were measured before, during, and after LBNP.
Results. Blood pressure and heart rate were significantly
lower in the metoprolol group throughout the study (P < 0.01).
GFR and RPF were similar in both groups at baseline, and no
change in renal hemodynamic values was detected at any level
of LBNP. However, a reduction in sodium excretion was ob-
served in the placebo group at −20 mbar, whereas no change
was detected in the metoprolol group. An increase in plasma
renin activity was also observed at −20 mbar in the placebo
group that was not observed with metoprolol.
Conclusion. The beta-blocker metoprolol prevents the
sodium retention induced by lower body negative pressure in
healthy subjects despite a lower blood pressure. The preven-
tion of sodium retention may be due to a blunting of the neu-
rohormonal response. These effects of metoprolol on the renal
response to LBNP may in part explain the beneficial effects of
this agent in heart failure patients.
Congestive heart failure (CHF) is characterized by an
activation of both the renin-angiotensin and the sympa-
thetic nervous systems, which are inversely correlated
with survival [1]. The renal response in CHF is charac-
terized by a marked sodium retention, which leads to an
undesirable vicious circle contributing to a further de-
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terioration of the disease [2]. Large clinical trials have
shown that long-term treatment with beta-blockers re-
duces morbidity and mortality in patients with CHF [3].
In addition to drugs that aim to improve the cardiac per-
formance in CHF, drugs that promote sodium and water
excretion are mandatory to relieve symptoms related to
pulmonary vascular congestion and to increased intravas-
cular volume and cardiac preload. Whether beta-blockers
modulate the renal response to a low cardiac output re-
sulting in a decreased renal perfusion has been poorly
investigated, at least in humans. Therefore, it would be of
interest to consider the effect of beta-blockers on renal
function and the resulting sodium and water retention
that characterizes CHF.
In patients with essential hypertension or with diabetic
or nondiabetic renal parenchymal diseases, the acute ad-
ministration of beta-blockers decreases both glomeru-
lar filtration rate (GFR) and renal plasma flow (RPF),
whereas chronic administration does not produce any
significant alteration of renal hemodynamics or any ef-
fect on sodium, potassium, or free water excretion [4, 5].
However, comprehensive information on the renal func-
tional effects of long-term beta-blocker therapy in pa-
tients with CHF is not currently available. Using rats with
myocardial infarction–induced CHF, DiBona et al have
demonstrated that long-term treatment with metoprolol
improves the natriuresis after both short- and long-term
sodium loads [6], indicating that an improvement in both
renal hemodynamics and renal sodium excretory capacity
might contribute the benefit of long-term treatment with
metoprolol in CHF. The possibility that part of the ben-
efit of long-term treatment with beta-blockers in CHF
may be mediated through an improvement in both re-
nal hemodynamics and renal sodium excretory capacity,
therefore, deserves further investigation in humans.
In healthy subjects, the application of a sustained lower
body negative pressure (LBNP) has been shown to induce
a progressive activation of neurohormonal systems, and
renal tubular and hemodynamic responses that mimics
the renal response observed in clinical conditions such as
CHF [7]. Using this method, we have recently shown in
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healthy subjects that selective blockade of angiotensin II
type 1 receptors with candesartan increase renal blood
flow and blunts the antinatriuresis induced by various
levels of LBNP [8].
The aim of the present study was to examine the effect
of the beta-blocker metoprolol on renal hemodynamics
and renal handling of sodium in subjects submitted to a
hemodynamic stress through the application of sustained
LBNP.
METHODS
Twenty healthy normotensive subjects were included in
this study. Their mean age was 25.6 (range 22 to 31 years).
Their mean height was 178 cm (range 164 to 190 cm)
and weight 70.4 kg (range 51 to 88 kg). A full medical
history and a complete physical examination were per-
formed before inclusion. They were free of any clinical
history of vasovagal syncope, postural hypotension, clin-
ical or laboratory evidence of heart, liver, kidney, and
endocrine diseases. Postural hypotension was excluded
by measuring blood pressure in the supine and then in
the upright position. The protocol was approved by the
local hospital ethical committee, and written informed
consent was obtained from each subject.
Study design
This was a randomized, double-blind parallel group
(placebo vs. metoprolol) study. Each subject was initially
randomized to receive either 200 mg of metoprolol tar-
trate once a day or a placebo for 14 days (from day 1 to
day 14). After 10 days of treatment, each volunteer was
submitted to 3 levels of lower body negative pressure
(0, −10, and −20 mbar corresponding respectively to 0,
−7.5, and −15 mm Hg) for 1 hour according to a triple
cross-over design. The LBNP method has been previ-
ously described [7]. Briefly, a negative pressure is applied
to the lower limbs using a Plexiglas box, connected to a
vacuum cleaner, sealed tightly around the waist. The mag-
nitude of negative pressure is transmitted by a manome-
ter. The study days took place 48 hours apart. The control
sequence (0 mbar) was randomized within each sequence,
and the lower level of LBNP was always tested before
the higher level to ensure good tolerance. From day 6 to
14, all subjects received a fixed and controlled sodium
diet (130 mmol Na/day) provided by the hospital. Water
intake was allowed ad libitum. Twenty-four–hour urine
collections were performed on days 8, 9, 11, and 13 to
monitor compliance to the diet, and to evaluate sodium,
potassium, and creatinine excretion. Subjects had to re-
frain from smoking and drinking caffeine-containing and
alcoholic beverages from day 8 to day 14.
Following an overnight fast, the volunteers kept supine
during the whole study day, except for voiding. An in-
fusion of inulin and para-aminohippurate (PAH) was
started to measure glomerular filtration rate (GFR) and
renal plasma flow (RPF), as described previously [9]. A
light breakfast and an oral water load of 5 mL/kg were in-
gested before 8:00 AM. Subsequently, subjects received a
fixed amount of water (150 mL/hour) to maintain a stable
urine output. After a 3-hour equilibrium period (T-240 to
T-60), the study days were divided into 1 hour at baseline
(T-60 to T0), 1 hour of LBNP (T0 to T60), and 2 hours
of recovery (T60 to T120 and T120 to T180). LBNP was
applied to subjects in the supine position and they were
not permitted to void during that period.
Vital signs (blood pressure, heart rate) were recorded
using an automated monitor placed on the left arm (Life-
sign Monitor; WelchAllyn, Skaneateles Falls, NY, USA).
Measurements were repeated every 5 minutes from time
T-30 to T+120 and every 15 minutes from T-120 to T-
30 and T+120 to T+180. Urine was collected hourly
throughout the study to measure urine output, urinary
electrolyte excretion (Na, K, uric acid), inulin, and PAH
excretion. Moreover, we measured endogenous trace
lithium in blood and in urine to assess the clearance of
lithium as an indicator of the reabsorption of sodium in
the proximal tubule, as described previously [7–9]. The
same parameters and the hematocrit (Ht) were mea-
sured hourly in the plasma. Blood was collected at times
T0, T+60, and T+120 for the measurements of plasma
norepinephrine (NE), epinephrine (E), aldosterone, and
plasma renin activity (PRA).
Analytical methods
Urinary and plasma sodium and potassium were
measured by flame photometry (IL-943; Instrumenta-
tion Laboratory, Milan, Italy) and creatinine by the
picric acid method (Cobas-Mira, Roche AG, Basel,
Switzerland). Plasma and urinary inulin and PAH were
determined by photometry (Autoanalyzer II-Technicon,
Bran & Luebbe, Norderstedt, Germany). Endogenous
trace lithium was measured by atomic absorption spec-
trophotometry [9–12]. Plasma renin activity [13], plasma
aldosterone [14], and plasma catecholamines [15] were
determined as reported previously.
Urinary electrolyte excretion rate was calculated as
Ux × V (mmol/min) and clearance (mL/min) calculated
using the standard formula Cx = Ux × V/Px, where Ux
and Px are the urine and plasma concentrations of x and
V is the urine flow rate in mL/min. The fractional excre-
tions were calculated as the clearance of x divided by the
GFR. Filtration fraction was calculated by dividing the
GFR by the RPF.
Fractional distal reabsorption of sodium (FDRNa) was
calculated as FDRNa = (1 − FENa/FELi), where FENa and
FELi indicate fractional excretion of sodium and lithium,
respectively. Renal blood flow (RBF) was calculated as
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Table 1. Characteristics of the subjects after the one week of placebo
or metoprolol administration and before stimulation with LBNP
Placebo Metoprolol P value
HR bpm 63.2 ± 3.6 50.91 ± 1.5 0.0052
MBP mm Hg 81.8 ± 2.4 73.9 ± 1.8 0.0174
UV mL/min 2.8 ± 0.4 2.6 ± 0.3 ns
GFR mL/min 126 ± 4 129 ± 6 ns
RFP mL/min 630 ± 29 645 ± 36 ns
RBF mL/min 1168 ± 57 1208 ± 85 ns
RVR mm Hg/mL/min 0.071 ± 0.002 0.062 ± 0.003 0.0249
UNaV lmol/min 99.3 ± 12.7 88.1 ± 6.4 ns
PRA ng/mL/h 1.15 ± 0.10 0.95 ± 0.10 ns
Aldosterone pg/mL 87.2 ± 6.8 75.6 ± 8.1 ns
Epinephrine pg/mL 43.0 ± 3.8 34.7 ± 4.0 ns
Norepinephrine pg/mL 203 ± 25 209 ± 16 ns
Values are mean ± SEM; N = 10 in each group.
Abbreviations are: HR, heart rate; MBP, mean blood pressure; UV, urine
output; GFR, glomerular filtration rate; RPF, renal plasma flow; RBF, renal
blood flow; RVR, renal vascular resistance; UNaV, sodium excretion; PRA,
plasma renin activity.
RBF = RPF/1 − Ht and renal vascular resistance (RVR)
as RVR = mean blood pressure/RBF.
Statistical analysis
All results are expressed as mean ± SEM. Within-
group analysis comparing the LBNP period to the
baseline period and the recovery periods were performed
using a one-way analysis of variance (ANOVA) analy-
sis followed by a Dunnet multiple comparison test. In-
tergroup comparisons were analyzed using a Student t
test. Values with a P < 0.05 were considered statistically
significant.
RESULTS
All volunteers completed the study, and each level of
LBNP was well tolerated. The baseline clinical charac-
teristics of the subjects (age, height, weight, systolic and
diastolic blood pressure, and heart rate) were comparable
in the placebo and metoprolol groups (data not shown).
The 24-hour urinary sodium excretion before and be-
tween each study days was also similar in the placebo
group (112 ± 6 mmol/day) and in the metoprolol group
(112 ± 7 mmol/day). After 10 days of drug administration,
blood pressure and heart rate were significantly lower in
the metoprolol group (Table 1). No differences in GFR
and RPF were observed but renal vascular resistance was
lower in the metoprolol group. The activity of the renin-
angiotensin system and plasma catecholamines were sim-
ilar in the 2 groups (Table 1).
Systemic and renal hemodynamic responses to LBNP
In the control group, systemic hemodynamic values did
not change from baseline to recovery except for a slight
decrease in heart rate and an increase in diastolic BP at
−20 mm Hg (Table 2). In the metoprolol group, baseline
blood pressure and heart rate were significantly lower
than in the control group, but again, no major changes
were observed during the 3 periods of LBNP except for
a further decrease in heart rate at −20 mbar and a slight
but significant increase in diastolic blood pressure during
the recovery period at −20 mbar. As far as renal hemo-
dynamics are concerned, GFR, RPF, filtration fraction,
RBF, and RVR did not change during or after LBNP
in each group. Mean blood pressure and, consequently,
renal vascular resistance were lower in the metoprolol
group at each level of LBNP.
Water and sodium tubular responses to LBNP
From baseline to recovery period, urinary volume did
not change except for a nonsignificant decrease during
LBNP, whatever the level of LBNP (Table 3). At 0 mbar,
the excretion of sodium (UNaV), as well as proximal and
distal sodium handling, remained stable during the LBNP
period in the placebo as well as in the metoprolol group.
However, at −20 mbar, sodium excretion decreased by
35% in the placebo group (P < 0.05 vs. baseline), whereas
the change was only 8% in the metoprolol group (P = ns
vs. baseline, Fig. 1). At this level, the absolute change in
urinary sodium excretion was −39 ± 13 lmol/min in the
placebo group versus −8.6 ± 6.1 lmol/min in the meto-
prolol group (P = 0.057). At −20 mbar, the decreased
sodium excretion was due essentially to an increased
reabsorption in the proximal tubule, as suggested by
the significant decrease in lithium clearance. The relative
decrease in lithium clearance was more pronounced in
the placebo group (−17%) than in the metoprolol group
(−12%), but the difference did not reach statistical sig-
nificance. At −20 mbar, a decrease in the fractional dis-
tal reabsorption of sodium (FDRNa) was found in both
groups during the recovery period and during LBNP.
Neurohormonal responses during the LBNP
and recovery periods
In the placebo group PRA tended to increase with the
2 levels of LBNP, followed by a decrease during the re-
covery period; however, the changes were only signifi-
cant at −20 mbar (Table 4). In the metoprolol group no
change in PRA was observed during the LBNP stimu-
lation (0 mbar, −10 mbar, or −20 mbar). At −20 mbar,
PRA was significantly lower during LBNP than in the
placebo group. At this level the relative change in PRA
was 21.5 ± 14% under placebo and (14 ± 11 in the meto-
prolol (P = ns). In the placebo group, aldosterone did not
seem to change except for a tendency to decrease during
the recovery period, especially at −20 mbar. However, at
−20 mbar, plasma aldosterone was lower during LBNP
in the metoprolol group (P < 0.05 vs. placebo). The per-
centage changes in plasma aldosterone were not differ-
ent between the 2 groups. In both groups, at each level of
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Table 2. Effects of metoprolol on systemic and renal hemodynamic responses to LBNP
Placebo Metoprolol
LBNP level Baseline LBNP Recovery Baseline LBNP Recovery
Systolic BP 0 mbar 114 ± 3 114 ± 3 117 ± 2 106 ± 2e 105 ± 2 107 ± 2
mm Hg −10 mbar 117 ± 4 121 ± 2 120 ± 3 105 ± 2e 108 ± 2 107 ± 2
−20 mbar 113 ± 4 114 ± 2 116 ± 3 105 ± 3 107 ± 2 105 ± 2
Diastolic BP 0 mbar 65 ± 2 67 ± 3 69 ± 1e 59 ± 1e 59 ± 2 63 ± 1
mm Hg −10 mbar 66 ± 3 71 ± 2a 70 ± 2 58 ± 2e 62 ± 2a 62 ± 2a
−20 mbar 64 ± 2 68 ± 3b 69 ± 2c 58 ± 2 61 ± 2 62 ± 2a
Heart rate 0 mbar 61 ± 3 57 ± 3c 57 ± 3c 51 ± 2f 49 ± 1a 48 ± 1c
beats/min −10 mbar 64 ± 5 60 ± 3b 59 ± 4b 51 ± 2e 47 ± 1b 46 ± 1c
−20 mbar 64 ± 3 60 ± 3b 57 ± 3c,d 50 ± 1f 49 ± 2 47 ± 1b
GFR mL/min 0 mbar 125 ± 6 126 ± 11 130 ± 10 128 ± 7 124 ± 8 125 ± 6
−10 mbar 129 ± 8 128 ± 9 128 ± 7 132 ± 8 126 ± 7 130 ± 9
−20 mbar 127 ± 5 122 ± 6 128 ± 10 127 ± 6 122 ± 5 125 ± 5
RPF mL/min 0 mbar 639 ± 36 595 ± 57 637 ± 52 629 ± 30 565 ± 32 611 ± 30
−10 mbar 602 ± 35 566 ± 35 602 ± 51 640 ± 45 591 ± 46 607 ± 45
−20 mbar 660 ± 36 593 ± 37 629 ± 46 668 ± 40 608 ± 34 616 ± 32
FF % 0 mbar 19.8 ± 0.8 21.5 ± 0.9a 20.8 ± 1.1 20.3 ± 0.6 22.0 ± 0.8a 20.5 ± 0.7
−10 mbar 21.9 ± 1.6 23.4 ± 2.3 22.5 ± 2.0 20.8 ± 0.6 21.8 ± 1.0 21.6 ± 0.9
−20 mbar 19.5 ± 0.7 20.8 ± 0.9 20.5 ± 0.9 19.4 ± 1.1 20.4 ± 0.8 20.4 ± 0.5
LBNP, lower body negative pressure period; BP, blood pressure; GFR, glomerular filtration rate; RPF, renal plasma flow; FF, filtration fraction.
aP < 0.05, bP < 0.01, cP < 0.01 vs. baseline; dP < 0.05 vs. LBNP; eP < 0.05, fP < 0.01. vs placebo.
Table 3. Effect of metoprolol on urinary output and urinary excretion of electrolytes during LBNP
Placebo Metoprolol
LBNP level Baseline LBNP Recovery Baseline LBNP Recovery
UV mL/min 0 mbar 2.9 ± 0.4 2.5 ± 0.3 2.9 ± 0.4 2.7 ± 0.4 3.0 ± 0.4 2.8 ± 0.4
−10 mbar 2.7 ± 0.4 2.6 ± 0.3 2.7 ± 0.4 2.7 ± 0.4 2.3 ± 0.3 3.3 ± 0.4c
−20 mbar 2.9 ± 0.5 2.2 ± 0.3 2.4 ± 0.3 2.4 ± 0.4 1.9 ± 0.3 2.8 ± 0.4
UNaV lmol/min 0 mbar 102 ± 12 83 ± 11 95 ± 11 92 ± 15 95 ± 18 114 ± 14a
−10 mbar 88 ± 17 73 ± 13 85 ± 11 69 ± 9 81 ± 8 91 ± 12
−20 mbar 108 ± 20 70 ± 8a 104 ± 14c 103 ± 6 95 ± 9 110 ± 11
Clear. Li mL/min 0 mbar 24.1 ± 2.5 25.2 ± 2.1 23.4 ± 1.5 22.1 ± 1.0 20.1 ± 1.3 19.8 ± 1.6
−10 mbar 27.3 ± 2.1 26.8 ± 2.6 25.8 ± 1.8 25.0 ± 23.3 23.3 ± 1.9 21.1 ± 1.7
−20 mbar 27.0 ± 2.5 22.3 ± 2.2a 23.6 ± 1.5 24.5 ± 1.0 21.5 ± 0.7a 20.1 ± 1.2
FDR Na % 0 mbar 96.8 ± 0.5 97.6 ± 0.3 97.1 ± 0.3 97.0 ± 0.5 96.4 ± 0.7 95.6 ± 0.6b
−10 mbar 97.8 ± 0.3 98.0 ± 0.3 97.4 ± 0.3 98.0 ± 0.2 97.4 ± 0.3 96.8 ± 0.3b
−20 mbar 97.2 ± 0.5 97.7 ± 0.3 96.8 ± 0.3d 97.1 ± 0.2 96.6 ± 0.3 96.1 ± 0.3a,c
Abbreviations are: LBNP, lower body negative pressure period; UV, urinary flow rate; UNaV, urinary excretion of sodium; Clear.Li, clearance of lithium; FDR Na,
fractional distal reabsorption rate of sodium.
aP < 0.05; bP < 0.01 vs. baseline; cP < 0.01; dP < 0.01 vs. LBNP.
suction, norepinephrine increased during LBNP and de-
creased during the recovery period. No significant change
in epinephrine levels was detected except for a decrease
in the metoprolol group after the −20 mbar stimulation.
DISCUSSION
Beta-adrenergic receptor blockers have become an es-
tablished therapy for patients with heart failure due to left
ventricular dysfunction [1, 3]. Several potential mecha-
nisms have been proposed to explain the beneficial effect
of these agents in heart failure [3, 16]. The purpose of the
present study was to investigate the effect of selective
beta-1 receptor blockade with metoprolol on the renal
hemodynamic values, and tubular responses to an unload-
ing of baroreceptors through the application of sustained
lower body negative pressure. This model of orthostatic
stress has been shown previously to reproduce in healthy
subjects the large shifts in effective arterial volume and,
hence, to mimic the neurohormonal and renal hemody-
namic changes observed in clinical heart failure [7]. Our
results demonstrate that 10 days’ administration of meto-
prolol to healthy subjects prevents the sodium retention
induced by LBNP despite the fact that the drug lowers
blood pressure. This effect of metoprolol does not appear
to be due to a change in renal hemodynamics but more
likely to a tubular effect due to the blunted activity of the
renin-angiotensin-aldosterone system.
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Fig. 1. Sodium retention is prevented by metoprolol during stimulation with lower body negative pressure.
Table 4. Effect of metoprolol on the renin-angiotensin-aldosterone and sympathetic nervous systems during LBNP
LBNP-0 LBNP-10 LBNP-20
Baseline LBNP Recovery Baseline LBNP Recovery Baseline LBNP Recovery
PRA ng/mL/h
Placebo 0.98 ± 0.16 0.86 ± 0.13 0.80 ± 0.16 1.32 ± 0.13 1.52 ± 0.38 0.80 ± 0.13 1.10 ± 0.12 1.25 ± 0.12 0.84 ± 0.11b
Metoprolol 1.02 ± 0.10 0.82 ± 0.09 0.70 ± 0.12 1.10 ± 0.12 0.86 ± 0.14 0.77 ± 0.15 0.73 ± 0.09c 0.79 ± 0.09b 0.69 ± 0.10
Aldosterone pg/mL
Placebo 84.2 ± 6.5 76.7 ± 10.2 70.8 ± 10.1 83.2 ± 9.2 75.4 ± 7.5 66.8 ± 8.2 85.4 ± 7.7 90.4 ± 9.8 69.3 ± 5.1a
Metoprolol 81.0 ± 10.6b 61.6 ± 7.1 57.8 ± 6.7 81.5 ± 10.1 73.5 ± 8.1 60.3 ± 6.1a 64.4 ± 8.8 6.8 ± 7.6c 56.4 ± 5.4
Norepinephrine pg/mL
Placebo 165 ± 28 160 ± 29 167 ± 46 213 ± 18 230 ± 19 219 ± 30 170 ± 16 206 ± 30 175 ± 29
Metoprolol 184 ± 21 194 ± 17 188 ± 23 235 ± 11 232 ± 16 211 ± 18 206 ± 25a 267 ± 33 225 ± 23
Epinephrine pg/mL
Placebo 42.1 ± 7.0 34.6 ± 5.7 27.0 ± 4.0 55.3 ± 6.9 60.9 ± 9.3 48.0 ± 6.5 36.5 ± 5.3 37.4 ± 6.5 45.5 ± 6.9
Metoprolol 32.8 ± 6.4 31.3 ± 5.0 34.9 ± 7.7 37.4 ± 5.5 34.0 ± 5.1c 36.0 ± 12.7 29.7 ± 4.8 41.5 ± 6.2 24.8 ± 4.4a,c
PRA, plasma renin activity; Values are mean ± SEM; N = 10 in each group.
aP < 0.05; bP < 0.01 LBNP vs. baseline and recovery period; cP < 0.05; dP < 0.01 metoprolol vs. placebo during same period.
The chronic oral administration of beta-adrenergic an-
tagonists is usually considered to have no effect on renal
hemodynamic values and urinary electrolyte excretion
[17, 18]. Yet, a natriuretic effect of beta-receptor blockade
has been reported in experimental congestive heart fail-
ure [6], in spontaneously hypertensive rats [19], and in pa-
tients with essential hypertension [20]. However, in other
studies, the long-term administration of beta-blockers has
been found to decrease renal plasma flow and/or urinary
sodium excretion [21, 22]. In our normotensive subjects,
no significant change in renal hemodynamics was found
after 1 week of administration, thereby confirming sev-
eral previous observations [17, 18, 20]. Although the lack
of change was expected, a possible explanation for the
variability of the renal response to beta-adrenergic recep-
tor blockade may reside in the type of beta-blocker used
in the study, as well as the drug formulation or doses used
for the study. Whether heart function and blood pressure
are normal or impaired at baseline may also influence
the renal hemodynamic response to beta-blockade. In
this study, we have used the same formulation and the
targeted dose of metoprolol used in the MERIT trial [23]
in healthy subjects. Of note, in contrast to the findings of
the present study, Frank et al found a significant decrease
in renal plasma flow in subjects during an almost similar
LBNP protocol [24]. However, some differences exist be-
tween the 2 studies, including the fact that Frank’s study
included hypertensive patients and the number of sub-
jects was greater. Moreover, the duration of the stimula-
tion was longer in our study (60 vs. 30 minutes), allowing
perhaps counter-regulatory mechanisms to operate.
Beta-receptor blockade may actually have a differ-
ent impact on renal function depending on the level of
stress to which the kidney is exposed. Indeed, we have
demonstrated in a previous study that increasing levels
of LBNP induce a sequential activation of the sympa-
thetic nervous system and of the renin-angiotensin sys-
tem, leading to a sodium retention before any effect on
renal hemodynamics occur [7]. Because tubular sodium
reabsorption is directly and indirectly modulated by
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neurohormonal activation in conditions of LBNP [25],
the main objective of the present study was to investigate
whether beta-receptor blockade with metoprolol would
modulate the renal hemodynamic and tubular response
to LBNP. Our data show that metoprolol had no particu-
lar effect on renal hemodynamics even under conditions
of stress. Yet, urinary sodium excretion was maintained
during the highest level of LBNP in subjects receiving
metoprolol. Of note, the ability of metoprolol to main-
tain sodium excretion was observed despite a reduction in
arterial pressure, suggesting an adjustment in renal hemo-
dynamics in order to maintain renal blood flow through
a possible resetting of the pressure-natriuresis relation-
ship. The ability of metoprolol to maintain a renal sodium
excretory capacity is comparable to that observed previ-
ously with the angiotensin II receptor blocker candesar-
tan, although the effect was globally less pronounced with
the beta-blocker than with the angiotensin II AT1 recep-
tor blocker [8].
The mechanism whereby metoprolol prevents sodium
retention during LBNP cannot be defined with precision
from our data because of the sensitivity of the meth-
ods used to investigate renal sodium handling. Yet some
explanations can be derived from our observations. Be-
cause the effect of norepinephrine on proximal tubular
sodium and water reabsorption is mediated essentially
by alpha-adrenergic receptors, a direct effect of metopro-
lol on proximal tubular sodium reabsorption is unlikely,
although it cannot entirely be ruled out because some
experiments have suggested an effect of beta-adrenergic
receptor on proximal sodium handling in some species
[25]. A more likely explanation is an indirect effect via
inhibition of renin secretion, which is in part beta-1
receptor–mediated [25]. Blockade of the activity of the
renin-angiotensin system may affect the proximal reab-
sorption of sodium through a decrease in angiotensin
II production and/or an attenuation of the activity of
the intra-renal sympathetic nervous system. An effect of
beta-blockers on renin secretion may also modulate dis-
tal sodium reabsorption via aldosterone. In accordance
with this hypothesis, the administration of metoprolol
prevented the activation of the renin-angiotensin sys-
tem in our subjects, as shown by lower values of PRA
and aldosterone during LBNP. Whether this effect on the
renin-angiotensin system had an impact on the intrarenal
activity of the sympathetic nervous system is more diffi-
cult to ascertain from our data. Indeed, the changes in
plasma norepinephrine levels were comparable during
the administration of metoprolol and placebo at 0 and
−10 mbar, and a slight but significant increase in plasma
norepinephrine was observed at −20 mm Hg in the meto-
prolol group. This would suggest that metoprolol had no
major influence on circulating catecholamines. However,
circulating plasma norepinephrine concentrations are not
a reliable indicator of the magnitude of the important
contribution of regional sympathetic outflow [26].
In line with previous observations, an increase in prox-
imal sodium reabsorption was found at −20 mbar in both
groups, confirming that LBNP promotes sodium reten-
tion in part through an effect on the proximal tubule. The
increase in norepinephrine during the −20 mbar LBNP
period might have caused a direct anti-natriuretic effect
through activation of alpha-adrenoreceptors known to be
present in the proximal tubule [16, 27–29] and left unop-
posed through selective beta-1 adrenoreceptor blockade.
Metoprolol does not appear to have a significant effect
on sodium handling by the proximal tubule, as the de-
crease in lithium clearance was not significantly different
with metoprolol and placebo, although the relative fall
was of lesser magnitude with the beta-blocker (−12% vs.
−17%). The difference in sodium excretion could possi-
bly be due to an indirect effect of metoprolol on the post-
proximal segments of the nephron mediated by the low
plasma aldosterone level. However, we could not con-
firm this hypothesis because no significant difference in
the fractional distal reabsorption of sodium was observed
in our study.
CONCLUSION
The results of the present study show that the adminis-
tration of metoprolol prevents sodium reabsorption de-
spite a lower blood pressure in healthy subjects whose
kidneys are stressed by a sustained LBNP. The effect of
metoprolol appears to be mediated primarily by a blunt-
ing of the activity of the renin-angiotensin-aldosterone
system, although the antinatriuretic effect of the beta-
blocker is less pronounced than that observed previously
with candesartan, a selective antagonist of angiotensin
2 AT1 receptors [8]. This observation thus provided
additional insights into potential mechanisms whereby
beta-receptor blockade clinically improves heart failure
patients. In addition to improving cardiac function, beta-
blockers may have a favorable impact on heart failure
patients by enhancing their ability to excrete sodium in-
dependently of the effect on cardiac performance.
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